Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04875754
PHASE1/PHASE2

A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis

Sponsor: ICM Biotech Australia Pty Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the safety, tolerability, and activity of ICM-203, a recombinant adeno-associated viral (AAV) vector that expresses a therapeutic gene that promotes cartilage formation, reduces joint inflammation and pain, as well as improves joint physical function, by injecting escalating doses of ICM-203 or matching placebo into the knee of subjects with mild to moderate knee osteoarthritis (OA).

Official title: A Phase 1/2a, Double-Blind, Placebo-Controlled Single Dose Escalation Study of Intra-Articular ICM 203 in Subjects With Kellgren-Lawrence Grade 2 or Grade 3 Osteoarthritis of the Knee

Key Details

Gender

All

Age Range

50 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2022-03-17

Completion Date

2026-12

Last Updated

2025-05-01

Healthy Volunteers

No

Interventions

GENETIC

ICM-203

Intra-articular injection

DRUG

Placebo

Intra-articular injection

Locations (2)

Royal Adelaide Hospital

Adelaide, South Australia, Australia

Barwon Health

Geelong, Victoria, Australia